3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Phase 2/3
1
Status
Completed
11
Unknown
8
Recruiting
3
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Classical hematology
3
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Venous Thromboembolism
3
Urologic Neoplasms
1
Urogenital Neoplasms
1
Pulmonary Embolism
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
555
Specimen Handling
459
Carboplatin
446
Magnetic Resonance Spectroscopy
427
Cyclophosphamide
412
Cisplatin
404
Gemcitabine
314
Radiotherapy
313
Bevacizumab
310
Paclitaxel
300
Biopsy
260
Drug Therapy
252
Capecitabine
241
Oxaliplatin
240
fludarabine
236
Nivolumab
226
venetoclax
225
Injections
214
Docetaxel
203
Fluorouracil
201
Dexamethasone
186
Radiosurgery
172
Rituximab
161
Pemetrexed
157
durvalumab
144
Standard of Care
143
atezolizumab
139
toripalimab
137
tislelizumab
137
Leucovorin
137
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Rivaroxaban
×
Clear all
NCT07270263
2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA
Recruiting
100 enrolled
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled
NCT05029063
2025-07-09
TRIM-Line
Ottawa Hospital Research Institute
Phase 3
Recruiting
1,828 enrolled